Lead Sponsor

Boehringer Ingelheim

Age

18 - 18 years

Sex

ALL

Healthy Volunteers

No

•1. Signed patient informed consent prior to study participation.
•2. HIV-1 infected male or female ?18 years of age.
•3. Have confirmed (2 consecutive) HIV RNA ?1000 copies/mL (one of the results must be within 3 months of enrollment into the study).
•4. Current HAART regimen contains a protease inhibitor for ?3 months.
•5. Physicians considering a change in the patient?s HAART regimen. f.) History of treatment with 2 or more protease inhibitors (including the current PI). Low dose ritonavir (i.e.\< 400 mg. bid) is not counted as one of the PIs.

•A patient with any of the following criteria will be excluded from participation in the study:
•1. ARV medication naive.
•2. Active opportunistic infection. c.) Known or suspected non-adherence to current HAART regimen as assessed by the investigator.